Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls

Recruiting Phase 2 Interventional Study
Arginine Vasopressin Deficiency Central Diabetes Insipidus Oxytocin Deficiency
Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
42 (estimated)
Sponsor
University Hospital, Basel, Switzerland · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The study aims to investigate whether intranasal oxytocin (OXT) improves sexual well-being in patients with Arginine Vasopressin Deficiency (AVP-D). The trial consists of two parts: Part A assesses the effect of OXT on sexual well-being and intimacy over a 7-day treatment period in participants in a stable partnership. Part B assesses the effect of a single dose OXT on sexual arousal, fear and emp…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria for healthy controls: * Adult healthy volunteers aged 18 years and above * Matched for age, sex, BMI, and menopause/hormonal contraceptives to patients * No medication, except hormonal contraception * At least mild impairment in sexual function and satisfaction, defined as an ASE…
Contacts

Mirjam Christ-Crain, Prof. MD

+41 61 328 70 80

mirjam.christ-crain@usb.ch

CONTACT

Cemile Bathelt

+41 61 556 54 07

cemile.bathelt@usb.ch

CONTACT